Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407 | 0.76 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL3751552 | 0.76 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL5770459 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL15353600 | 0.71 | — | — | |
| SCHEMBL27552944 | 0.71 | — | — | |
| Water SCHEMBL2864553 | 0.71 | — | — | |
| SCHEMBL2940431 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL2142590 | 0.71 | — | — | |
| Fluoride SCHEMBL634472 | 0.71 | — | — | |
| Bromide SCHEMBL4443445 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789553-B1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8013136-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7723512-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| EP-0901500-B1 | IN SITU PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE IN SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-6005094-A | MIXTURE OF AN ACID RESISTANT, ANTISENSE OLIGONUCLEOTIDE AND A CARRIER; FOR ORAL ADMINISTRATION | GENTA INCORPORATED (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0901500-A1 | $i(IN SITU) PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE IN SYNTHESIS OF OLIGONUCLEOTIDES | HYBRIDON, Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997042208-A1 | IN SITU PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE IN SYNTHESIS OF OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0690716-A4 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | UNIV JOHNS HOPKINS (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0690716-A1 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994015619-A1 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | THE JOHNS HOPKINS UNIVERSITY (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | PNP, RNMT, SLC29A2 | ALDH1A1 1235/4885TSHR 3300/4885 |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | ALDH1A1 1576/4885TSHR 3873/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ALDH1A1 1405/4885TSHR 3318/4885 |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | ALDH1A1 1576/4885TSHR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.